RAISING ALPHA-1 AWARENESS

November is Alpha-1 Awareness Month. Alpha-1,[1] often called genetic COPD, is estimated to affect up to 3.4 million[2] people worldwide who are severely deficient in alpha-1 antitrypsin. The majority of these people, however, are unaware that they have alpha-1. Here's what Grifols is doing to change that around the world.

DIAGNOSIS

Over the last 10 years, Grifols has contributed through sponsored services to the testing of approximately 850,000 COPD patients, and more than…

- **750,000** COPD patients ruled out for alpha-1
- **98,000** patients identified with deficient alleles
- **7,900** patients diagnosed with severe alpha-1-antitrypsin deficiency

RESEARCH AND DEVELOPMENT

Over the last 5 years, Grifols has invested more than $150 million in research and development:

- SPARTA (ongoing): The largest randomized controlled trial evaluating the efficacy of augmentation therapy
- New approaches to alpha-1 treatment, including different formulations
- More than **$2 million** provided to investigator-sponsored researchers for alpha-1 preclinical and clinical research

ACHIEVEMENTS

Since the previous Alpha-1 Awareness Month, Grifols has achieved several noteworthy milestones:

NOVEMBER 2017	JUNE 2018	SEPTEMBER 2018	NOV 2017 - OCT 2018
Grifols awarded FDA and CE mark approval for non-invasive alpha-1 diagnostic technology using saliva	Grifols announced availability of PROLASTIN®-C LIQUID (alpha$_1$-proteinase inhibitor [human]) in the U.S.	Grifols granted **€50,000** to alpha-1 researchers at the ALTA Awards	Grifols diagnosed more than **800** patients worldwide with severely deficient alpha-1 antitrypsin

PROMOTING AWARENESS

"Grifols is fully committed to alpha-1 patients, offering the most innovative treatments and providing resources to help them manage their condition. As we recognize **Alpha-1 Awareness Month** this November, we are proud to strengthen our commitment to this community by investigating new testing options, developing new formulations for patient and healthcare provider convenience and working to discover the alpha-1 treatment of the future."

Angela M. Davis, M.D. Grifols Global Medical Director, Pulmonary

GRIFOLS

1. Alpha-1-antitrypsin deficiency.
2. Brantly M et al. Characteristics of patients with rare PI*F and PI*I alleles from the US National Detection Program for Alpha-1-Antitrypsin Deficiency. Poster presented at: American Thoracic Society Annual Congress, Topics In Alpha-1-Antitrypsin Deficiency; May 20, 2018; San Diego, CA.